Nuvectis Pharma (NVCT) news
Recent news
Nuvectis' NXP200 to seek US ind filing in 4Q 2026
AInvest Wire · Sep 24, 2026Nuvectis Pharma - NXP200 granted breakthrough therapy designation by China CDE for BRAF V600-mutant glioma
Nuvectis Pharma, Inc. (NASDAQ: NVCT) has announced that its in-licensed compound NXP200 (HSK42360), a paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation by the China Center for Drug Evaluation (CDE) for the treatment of BRAF V600-mutant glioma. This designation is…
AInvest Wire · Sep 24, 2026Nuvectis Pharma - base prospectus covers offer and sale of up to $200 mln of securities - SEC filing
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has filed a base prospectus with the U.S. Securities and Exchange Commission (SEC) covering the potential offer and sale of up to $200 million of its securities. The filing, made under a shelf registration statement on Form S-3 (File No. 333-293459), was…
AInvest Wire · Aug 21, 2026Nuvectis: expected gross proceeds of $100M from offering
AInvest Wire · Jun 30, 2026Nuvectis Pharma prices 5M shares of common stock at $20/shr
AInvest Wire · Jun 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.